semaglutide 503b FDA Proposal on Semaglutide, Tirzepatide, Liraglutide Exclusion from Bulk List | Chris Munoz, Pharm.D. posted on the topic 503B Compounding Pharmacy | Clinical

Conclusions In sum, the findings provide genetic evidence of associations between BMI-related GLP-1R activation and reduced risks of BD and MDD, as well as a better well-being spectrum

Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist (RA) drug

These findings suggest that in men with obesity or type 2 diabetes, incretin-based therapy may help restore healthy testosterone levels, particularly when low testosterone is related to obesity, she told Healthline

Telehealth coverage is described as nationwide, but the only states explicitly advertised in detail are Florida, Georgia, North Carolina, and South Carolina

Cotadutide (MEDI0382) is the most extensively developed dual GLP-1/glucagon receptor agonist, showing significant improvements in glucose control, BW (likely mediated by reduced energy intake rather than increased energy expenditure), hepatic fat, and albuminuria in a small RCT on patients with T2D and overweight or obesity 45,46

These changes can be surprising, especially if your periods were previously regular